I joined Solve as CEO in 2020, when we embarked on a strategy that connected ME/CFS with Long Covid, which was just emerging at that time as a clinical condition. Solve formally expanded our mission and began to use a broader term, “infection associated diseases,” particularly in the advocacy space and in legislative language.
In the years that have followed, we’ve seen ample evidence pointing to the similar biological underpinnings of these conditions, patients have begun to drive research as never before, and technological advancements have created new opportunities to improve outcomes for the millions who suffer from these diseases. Together, these changes have created a rare opportunity for breakthroughs.
We’re committed to meeting this pivotal moment. That’s why we’re making changes that will emphasize:
- Direct research
- Catalyzing the research and development ecosystem
- Patient empowerment
- Advocacy and Policy
In addition to launching our new patient-centric programs, the Lived Experience Taskforce and the Long Covid Patient Leadership Advancement Network (LC-PLAN), we’ll soon welcome a new Chief Research Officer and transition to the new data platform Solve Together.
An evolution of our You + ME Registry and Biobank and co-designed by patients, Solve Together will allow participants to connect wearables, download reports for doctor visits, link electronic health records, and provide data with less time and energy. You’ll find that it offers extensive advantages to both users and researchers. In the weeks to come, we’ll share details about Solve Together, and more information about how you can get involved.
All of these changes are in service to our greatest priorities: diagnostics, treatments, cures, and community. Thank you for joining us in these exciting steps forward, and for always being our partner in progress.